Active substance
Levocarnitine
- US FDA 18
- Health Canada 4
- US price lines 3
- NHS prices 2
- Safety 3
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CARNITOR | 330MG | tablet · oral | LEADIANT BIOSCI INC | Prescription | 27 Dec 1985 |
| CARNITOR | 1GM/10ML | solution · oral | LEADIANT BIOSCI INC | Prescription | 10 Apr 1986 |
| CARNITOR SF | 1GM/10ML | solution · oral | LEADIANT BIOSCI INC | Prescription | 10 Apr 1986 |
| CARNITOR | 200MG/ML | injectable · injection | LEADIANT BIOSCI INC | Prescription | 16 Dec 1992 |
| LEVOCARNITINE | 200MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 29 Mar 2001 |
| LEVOCARNITINE | 200MG/ML | injectable · injection | AM REGENT | Prescription | 22 Jun 2001 |
| LEVOCARNITINE | 1GM/10ML | solution · oral | RISING | Prescription | 10 Aug 2004 |
| LEVOCARNITINE | 330MG | tablet · oral | RISING | Prescription | 20 Sep 2004 |
| LEVOCARNITINE | 1GM/10ML | solution · oral | NOVITIUM PHARMA | Prescription | 14 Aug 2019 |
| LEVOCARNITINE SF | 1GM/10ML | solution · oral | NOVITIUM PHARMA | Prescription | 14 Aug 2019 |
| LEVOCARNITINE | 1GM/10ML | solution · oral | SCIEGEN PHARMS | Prescription | 10 Nov 2021 |
| LEVOCARNITINE | 330MG | tablet · oral | NOVITIUM PHARMA | Prescription | 9 Dec 2022 |
| LEVOCARNITINE | 200MG/ML | injectable · injection | DEVA HOLDING AS | Prescription | 30 Jun 2025 |
| LEVOCARNITINE | 200MG/ML | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 2 Jul 2026 |
| LEVOCARNITINE | 200MG/ML | injectable · injection | GLAND | Prescription | 30 Sep 2026 |
| CARNITOR | 1GM/10ML | solution · oral | LEADIANT BIOSCI INC | Discontinued | 27 Dec 1985 |
| LEVOCARNITINE | 200MG/ML | injectable · injection | TEVA PHARMS USA | Discontinued | 29 Mar 2001 |
| LEVOCARNITINE | 1GM/10ML | solution · oral | HIKMA PHARMS | Discontinued | 25 Oct 2007 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CARNITOR | 02144328 | 330 MG | TABLET · ORAL | LEADIANT BIOSCIENCES, INC |
| CARNITOR | 02144336 | 100 MG / ML | SOLUTION · ORAL | LEADIANT BIOSCIENCES, INC |
| CARNITOR | 02144344 | 200 MG / ML | SOLUTION · INTRAVENOUS | LEADIANT BIOSCIENCES, INC |
| ODAN LEVOCARNITINE | 02492105 | 100 MG / ML | SOLUTION · ORAL | ODAN LABORATORIESLTD |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LEVOCARNITINE 1 G/10 ML SOLN | $0.14503 | per ML | 23 Sep 2026 |
| US NADAC | LEVOCARNITINE 330 MG TABLET | $0.67062 | per EA | 23 Sep 2026 |
| US NADAC | LEVOCARNITINE SF 1 G/10 ML SOL | $0.25217 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Levocarnitine 1.5g/5ml oral solution paediatric sugar free | £71.40 | 20 ml | 1 Oct 2026 |
| NHS Drug Tariff | Levocarnitine 1.5g/5ml oral solution paediatric sugar free | £178.50 | 50 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 17 Apr 2018 CARNITOR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 17 Apr 2018 CARNITOR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 17 Apr 2018 CARNITOR SF — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.